Global IN-SILICO DRUG DISCOVERY Market Research Report 2023-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2029

Global IN-SILICO DRUG DISCOVERY Market Research Report 2023-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2029

Market Overview:

The latest research study on the global IN-SILICO DRUG DISCOVERY market finds that the global IN-SILICO DRUG DISCOVERY market reached a value of USD 2728.57 million in 2022. It’s expected that the market will achieve USD 5695.87 million by 2028, exhibiting a CAGR of 13.05% during the forecast period.

Market Drivers

Readmission Rate is the percentage of admitted patients who return to the hospital within seven days of discharge. Hospital readmission measures are not only considered quality measures, but also a means to charge more medical expenses in disguise.

Medical error is a serious public health problem. It is challenging to find consistent causes of errors, and even if errors are found, to provide consistent feasible solutions to minimize recurring events. By identifying the occurrence of adverse events, learning from them and working hard to prevent them, the safety of patients can be improved.

Then, this will cause hospitals or other institutions to increase their investment in in-silico drug discovery and improve the accuracy of medication in the medical process, thereby avoiding the occurrence of medical errors and the increase of readmission rate. Therefore, reducing medical errors and readmission rates are the main driving forces of the in-silico drug discovery market.

The in-silico biomarker discovery platform can promote the integration and analysis of patient-centric multi-omics, clinical and biomedical data; early detection of new disease biomarkers.

Biomarker discovery solutions can:

Rapid disease diagnosis

Predict prognosis, drug resistance and patient response

Develop personalized medicine strategies.

Sedentary lifestyles, unhealthy eating habits and lack of exercise have increased the global burden of chronic diseases (especially cancer, diabetes, and cardiovascular diseases), leading to the growth of the biomarker identification market.

The growth of the biomarker identification market has provided in-silico drug discovery with more advanced technology and improved its accuracy, thereby driving the development of the in-silico drug discovery market.

Region Overview:

North America had the highest growth rate of all regions.

Company Overview:

Charles River is one of the major players operating in the IN-SILICO DRUG DISCOVERY market, holding a share of 13.8% in 2020.

Charles River Laboratories is a leading provider of drug discovery and development services. About half of the company's revenue comes from drug discovery and preclinical testing, and one fourth comes from the manufacturing support segment.

Certara USA, Inc. provides drug development software and services. The Company offers drug development and clinical pharmacology strategy, regulatory strategy, writing and submission, as well as HEOR & market access solutions. Certara serves biopharmaceutical and medical technology customers worldwide.

Segmentation Overview:

Among different product types, Consultancy as a Service segment is anticipated to contribute the largest market share in 2027.

Application Overview:

By application, the Contract Research Organization segment occupied the biggest share from 2017 to 2022.

Key Companies in the global IN-SILICO DRUG DISCOVERY market covered in Chapter 3:

Ligand
Selvita
BioDuro
Charles River
Albany Molecular Research Inc.
Certara
GVK Biosciences Private Limited
Evotec A.G.
WuXi AppTec
Collaborative Drug Discovery Inc.

In Chapter 4 and Chapter 14.2, on the basis of types, the IN-SILICO DRUG DISCOVERY market from 2018 to 2029 is primarily split into:

Software as a Service
Consultancy as a Service

In Chapter 5 and Chapter 14.3, on the basis of Downstream Industry, the IN-SILICO DRUG DISCOVERY market from 2018 to 2029 covers:

Contract Research Organization
Pharmaceutical Industry
Academic and Research Institutes
Others

Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2018-2029) of the following regions are covered in Chapter 8 to Chapter 14:

North America (United States, Canada)
Europe (Germany, UK, France, Italy, Spain, Russia, Netherlands, Turkey, Switzerland, Sweden)
Asia Pacific (China, Japan, South Korea, Australia, India, Indonesia, Philippines, Malaysia)
Latin America (Brazil, Mexico, Argentina)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa)